KR20240055717A - 뇌 종양 치료에 사용하기 위한 egfr의 (1h-피롤로[2,3-b]피리딘-1-일)피리미딘-2-일-아미노-페닐-아크릴아미드 억제제 - Google Patents

뇌 종양 치료에 사용하기 위한 egfr의 (1h-피롤로[2,3-b]피리딘-1-일)피리미딘-2-일-아미노-페닐-아크릴아미드 억제제 Download PDF

Info

Publication number
KR20240055717A
KR20240055717A KR1020247001434A KR20247001434A KR20240055717A KR 20240055717 A KR20240055717 A KR 20240055717A KR 1020247001434 A KR1020247001434 A KR 1020247001434A KR 20247001434 A KR20247001434 A KR 20247001434A KR 20240055717 A KR20240055717 A KR 20240055717A
Authority
KR
South Korea
Prior art keywords
compound
alkyl
cancer
pharmaceutically acceptable
egfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247001434A
Other languages
English (en)
Korean (ko)
Inventor
진 자오
윌리엄 컨스
Original Assignee
다나-파버 캔서 인스티튜트 인크.
크림슨 바이오팜 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다나-파버 캔서 인스티튜트 인크., 크림슨 바이오팜 아이엔씨. filed Critical 다나-파버 캔서 인스티튜트 인크.
Publication of KR20240055717A publication Critical patent/KR20240055717A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247001434A 2021-06-22 2022-06-22 뇌 종양 치료에 사용하기 위한 egfr의 (1h-피롤로[2,3-b]피리딘-1-일)피리미딘-2-일-아미노-페닐-아크릴아미드 억제제 Pending KR20240055717A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163213301P 2021-06-22 2021-06-22
US63/213,301 2021-06-22
US202163257907P 2021-10-20 2021-10-20
US63/257,907 2021-10-20
PCT/US2022/034574 WO2022271861A1 (en) 2021-06-22 2022-06-22 (1h-pyrrolo[2,3-b]pyridin-1-yl)pyrimidin-2-yl-amino-phenyl--acrylamide inhibitors of egfr for use in the treatment of brain tumors

Publications (1)

Publication Number Publication Date
KR20240055717A true KR20240055717A (ko) 2024-04-29

Family

ID=82693978

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247001434A Pending KR20240055717A (ko) 2021-06-22 2022-06-22 뇌 종양 치료에 사용하기 위한 egfr의 (1h-피롤로[2,3-b]피리딘-1-일)피리미딘-2-일-아미노-페닐-아크릴아미드 억제제

Country Status (7)

Country Link
US (1) US20240293405A1 (https=)
EP (1) EP4358957A1 (https=)
JP (1) JP2024523558A (https=)
KR (1) KR20240055717A (https=)
AU (1) AU2022297453A1 (https=)
CA (1) CA3224994A1 (https=)
WO (1) WO2022271861A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4367116A4 (en) * 2021-07-07 2025-04-30 Crimson Biopharm Inc. Crystalline polymorphs of epidermal growth factor receptor inhibition, and compositions and methods therefor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US20040171630A1 (en) * 2001-06-19 2004-09-02 Yuntae Kim Tyrosine kinase inhibitors
WO2007005643A2 (en) 2005-07-01 2007-01-11 Concert Pharmaceuticals Inc. Novel aryloxyphenylpropanamines
WO2007005644A2 (en) 2005-07-01 2007-01-11 Concert Pharmaceuticals Inc. Novel aryloxypropanamines
AU2006275702A1 (en) 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
KR101380190B1 (ko) 2005-07-29 2014-04-11 콘서트 파마슈티컬즈, 인크. 벤조 〔ｄ〕〔１,３〕―디옥솔 유도체
WO2015188777A1 (en) * 2014-06-12 2015-12-17 Shanghai Fochon Pharmaceutical Co Ltd Certain protein kinase inhibitors
WO2016105525A2 (en) * 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Novel pyrimidines as egfr inhibitors and methods of treating disorders
US20210101881A1 (en) * 2018-02-12 2021-04-08 Ancureall Pharmaceutical (Shanghai) Co., Ltd. Pyrimidine compound, preparation method thereof and medical use thereof

Also Published As

Publication number Publication date
AU2022297453A1 (en) 2024-01-04
JP2024523558A (ja) 2024-06-28
WO2022271861A1 (en) 2022-12-29
US20240293405A1 (en) 2024-09-05
EP4358957A1 (en) 2024-05-01
CA3224994A1 (en) 2022-12-29

Similar Documents

Publication Publication Date Title
JP7260718B2 (ja) ジアザインドール誘導体及びそのＣｈｋ１阻害剤としての使用
EP3317273B1 (en) Inhibitors of egfr and methods of use thereof
CN108290872B (zh) 作为DUBs抑制剂的氰基吡咯烷衍生物
JP5658664B2 (ja) １，２−二置換複素環式化合物
KR20120055571A (ko) 종양성 또는 자가면역 질환 치료용 전구약물로서의 푸라자노벤즈이미다졸
EP2685980B1 (en) Methods and use of bifunctional enzyme-building clamp-shaped molecules
US20170226084A1 (en) Pyridine-substituted 2-aminopyridine protein kinase inhibitors
ES2988563T3 (es) Inhibidores de la quinasa RHO y composiciones y métodos de uso de los mismos
KR20240055717A (ko) 뇌 종양 치료에 사용하기 위한 egfr의 (1h-피롤로[2,3-b]피리딘-1-일)피리미딘-2-일-아미노-페닐-아크릴아미드 억제제
JP2021514398A (ja) Ｅｇｆｒ阻害剤の組合せ医薬製剤およびその使用法
WO2017049401A1 (en) New benzimidazoles derivatives as tec kinases family inhibitors
JP2021514399A (ja) Ｅｇｆｒの阻害剤およびその使用法
WO2020229595A1 (en) Quinazoline-2,4-dione derivatives as parp inhibitors
CN113490669A (zh) 一类具有降解Btk活性的化合物
CN117979968A (zh) 用于治疗脑肿瘤的EGFR抑制剂(1H-吡咯并[2,3-b]吡啶-1-基)嘧啶-2-基-氨基-苯基-丙烯酰胺
CN102802628A (zh) 取代的4-羟基嘧啶-5-甲酰胺
WO2019001307A1 (zh) 一种酰胺类化合物及包含该化合物的组合物及其用途
JP2020518563A (ja) 抗ガン幹細胞性薬物
WO2017092523A1 (zh) 一种稠合嘧啶化合物及包含该化合物的组合物及其用途
EP4053121A1 (en) Novel heterocyclic-substituted pyrimidine derivative exhibiting cancer cell growth inhibitory effect, and pharmaceutical composition containing same
KR20260015777A (ko) 종양 산화 환원-활성화 6-티오푸린 함유 이량체 화합물
WO2026012504A1 (zh) 用于降解目标蛋白的crbn结合化合物及其应用
CN121824433A (zh) 一种解旋酶抑制剂、其制备方法及其用途
KR20250096635A (ko) Tyk2 억제제 및 이의 용도
EP4317143A1 (en) Bicyclic heterocyclic fgfr4 inhibitor, pharmaceutical composition and preparation comprising same, and application thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000